Pentoxifylline tab n / an kish.rastv. 100mg 60 pieces


Pentoxifylline tab n / an kish.rastv. 100mg 60 pieces



Active substance:
1 tablet contains: pentoxifylline – 100,000 mg ;.
Product form:
The tablets, enteric coated 100 mg.
• Hypersensitivity to pentoxifylline, other methylxanthines or to any component of the drug; • massive bleeding, extensive hemorrhages in the retina of the eye; • acute myocardial infarction; • bleeding in the brain; • expressed atherosclerosis of the coronary arteries; • pregnancy; • breastfeeding; • Children up to age 18; • lactose intolerance, lactase deficiency and syndrome of glucose-galactose malabsorption.
100 mg
• Obstructive atherosclerotic peripheral arterial disease or diabetic origin (e.g., intermittent claudication, diabetic angiopathy); • trophic disorders (e.g., trophic ulcer tibia, gangrene); • cerebral circulatory disorders (cerebral atherosclerosis effects, such as poor concentration, dizziness, memory impairment), ischemic and post stroke state; • circulatory disturbances in the network and the choroid; • otosclerosis, degenerative changes in the background pathology of vessels of the inner ear and hearing loss.
pharmachologic effect
Pharmacological group:
Vasodilating agent.
Pharmacological properties:
Pentoxifylline drug decreases blood viscosity and improves the flow properties of the blood (flowability) due to: – improve the impaired erythrocyte deformability; – reducing platelet aggregation and erythrocytes; – reducing the concentration of fibrinogen; – reducing the activity of leukocytes, and reducing the adhesion of leukocytes to the vascular endothelium. The active substance preparation contains Pentoxifylline xanthine derivative – pentoxifylline. Its mechanism of action is related to inhibition of phosphodiesterase and the accumulation of cyclic adenosine monophosphate (cAMP) in vascular smooth muscle cells of blood corpuscles and cells. Exerting slight myotropic vasodilator action, pentoxifylline somewhat reduces the total peripheral vascular resistance and slightly increasing coronary vessels. Pentoxifylline has a weak positive inotropic effect on the heart. Improves microcirculation in areas of impaired circulation. Treatment with Pentoxifylline leads to improvement of symptoms of cerebral blood flow. When occlusive diseases of the peripheral arteries leading to the use of pentoxifylline elongation distance away, elimination of night cramps in the calves and disappearance of pain at rest.
Conditions of supply of pharmacies
Dosing and Administration
The dosage is set by the doctor according to the individual patient. The drug should be swallowed whole during or immediately after eating, drinking plenty of water. The usual dose is: Pentoxifylline one tablet three times a day, followed by increasing doses up to 200 mg 2-3 times a day. The maximum single dose – 400 mg. The maximum daily dose – 1200 mg. In peripheral artery occlusive disease stage II (intermittent claudication) Pentoxifylline recommended dose is 1200 mg per day (preferably in the form of sustained-release tablets of 400 mg three times a day or 600 mg 2 times a day). Patients with impaired renal function (creatinine clearance less than 30 mL / min), the dosage may be reduced to 1-2 tablets per day. Reducing the dose, taking into account the individual tolerance, it is necessary in patients with severely impaired hepatic function. Treatment can be initiated with small doses in patients with low blood pressure, as well as in patients at risk due to a possible decrease in blood pressure (patients with severe coronary artery disease or a hemodynamically significant stenosis of the cerebral vessels). In these cases, the dose can be increased only gradually.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review